Accelerating Biotherapeutic Pipelines from Concept to Clinic

Stage 1: Target Discovery & Functional Epitope Mapping
We rapidly translate complex biological data into high-confidence, druggable pathways.
• Automated Target Validation: Our platform scans global scientific data to identify novel disease pathways and confirm target relevance.
• Precision Epitope Targeting: We predict and prioritize highly functional, disease-specific binding sites to ensure optimal therapeutic impact from the start.

Stage 2: De Novo Antibody Generation & Optimization
We move past traditional, slow screening libraries to intentionally create the ideal molecule from scratch.
• Structural Generation: Our generative platform designs high-affinity antibody candidates against challenging, novel targets, even when prior structural data is unavailable.
• Simultaneous Multi-Property Optimization: We virtually evaluate and score millions of candidates in parallel, co-optimizing them for target affinity, stability, and low immunogenicity before they ever touch a lab bench.

Stage 3 & 4: Predictive Screenings & Translational Pharmacology
We replace traditional linear testing with an intelligent feedback loop where empirical lab data continuously refines our predictive models.
•High-Impact Screening Loops: Our engine uses early assay data to accurately predict which candidates are most likely to succeed in vivo, maximizing downstream hit rates.
• Simulated Pharmacology: We model target engagement and tissue distribution early, running thousands of virtual scenarios to optimize candidate behavior prior to advanced testing.

Stage 5 & 6: Pre-emptive PK/Tox & Commercial Developability
We eliminate downstream liabilities by forecasting a drug's behavior in the body and its commercial viability at the earliest design phase.
• Advanced PK & Safety Forecasting: Our predictive models map out clearance, biodistribution, and potential toxicity risks for complex biotherapeutic modalities.
• Early Developability Assessment: We screen out problematic candidates prone to manufacturing hurdles or aggregation early, ensuring only the most stable, scaleable, and safe assets advance toward the clinic.